Novartis confirmed that a BLA for accelerated approval of del-zota in Duchenne muscular dystrophy amenable to exon 44 skipping was submitted to the FDA.
Korean translation
노바티스는 엑손 44 스키핑 적용 가능 뒤센근이영양증 치료제 델-조타의 가속승인 BLA를 FDA에 제출했음을 확인함.
Novartis confirmed that a BLA for accelerated approval of del-zota in Duchenne muscular dystrophy amenable to exon 44 skipping was submitted to the FDA.
Korean translation
노바티스는 엑손 44 스키핑 적용 가능 뒤센근이영양증 치료제 델-조타의 가속승인 BLA를 FDA에 제출했음을 확인함.